Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2025-05-23

EMA Authorised: Lacosamide UCB (lacosamide) — UCB Pharma S.A.

View source ↗

Summary

The European Medicines Agency authorised a lacosamide product (Lacosamide UCB) from UCB Pharma S.A., for partial epilepsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lacosamide UCB (lacosamide)

Snippet

Status: Authorised. Therapeutic area: Epilepsies, Partial. MAH: UCB Pharma S.A.. Decision date: 12/05/2025